Filing Flows › Nuo Therapeutics (AURX) › Q1 2026
Nuo Therapeutics (AURX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Nuo Therapeutics (AURX) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), +169% from a year earlier and +19% from the quarter before. Operating margin was -34.3%, net loss $618K (47.5% of revenue).
Nuo Therapeutics, Q1 2026: revenue $1.3M (+169% year over year), operating margin -34.3%, net loss $618K, operating cash flow −$784K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | +19% | +169% |
| Operating profit | −$446K | — | — |
| Net earnings | −$618K | — | — |
| Operating cash flow | −$784K | — | -43074% |
What changed
Revenue was $1.3M in Q1 2026, up 169% year over year and up 19% from the previous quarter. Product was the largest line at 94% of revenue. Product added $740K year over year (up 153%), 90% of the total change.
Gross margin was 65.3%, down 9.8 points from Q1 2025. Operating costs exceeded revenue by $446K, an operating margin of -34.3%. Operating expenses grew 17% against revenue growth of 169%. The quarter ended with a net loss of $618K, wider than the previous quarter's $578K loss.
Operating cash flow was −$784K. Non-cash charges added back $22K of depreciation and $24K of share-based compensation. Working capital and other items used $212K. Capital expenditures of $1K exceeded it, leaving free cash flow of −$785K.
Questions
What was Nuo Therapeutics' revenue in the first quarter 2026?
Nuo Therapeutics (AURX) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), +169% from a year earlier and +19% from the quarter before.
Was Nuo Therapeutics profitable in the first quarter 2026?
Operating loss was $446K (-34.3% of revenue) and net loss $618K.
Source: Nuo Therapeutics 10-Q on SEC EDGAR.